Mitsubishi UFJ Asset Management Co. Ltd. Has $17.16 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 9.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 807,886 shares of the company’s stock after buying an additional 70,978 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $17,159,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $50,000. Ameliora Wealth Management Ltd. bought a new position in Teva Pharmaceutical Industries in the fourth quarter valued at $66,000. IFP Advisors Inc lifted its position in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after buying an additional 1,960 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Teva Pharmaceutical Industries during the 4th quarter worth about $104,000. Finally, Assetmark Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 1,370.3% during the 4th quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock worth $115,000 after buying an additional 4,851 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday. Piper Sandler upped their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Barclays dropped their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Finally, Bank of America decreased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $15.06 on Monday. The company’s 50-day moving average is $17.21 and its 200-day moving average is $18.12. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm has a market capitalization of $17.07 billion, a PE ratio of -10.38, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.51 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.